'Different' GSK settles for $3 billion with US government
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline says it has reached an agreement in principle with the US government to conclude its "most significant ongoing" federal investigations, investigations that GSK CEO Andrew Witty said " do not reflect the company that we are today." The cost of clearing up the legal messes amount to around $3 billion, not peanuts but less than the £2.9 billion ($4.6 billion) that the company had set aside for current legal provisions.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.